Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Bioheart, Inc. (BHRT) Agrees to Licensing Agreement with Airspeed Equity 0 comments
    Jul 29, 2011 2:07 PM | about stocks: BHRT
    Located in Sunrise, Florida, Bioheart has quickly gained acclaim through their focus on completion of the Phase II/III MARVEL study for chronic heart failure using MyoCell. Today, Bioheart took a major step towards prominence with the announcement they have agreed to terms with Airspeed Equity, LLC, to license four separate Bioheart patents.

    The proposed license agreement will provide a multitude of benefits for both companies. Airspeed will be granted the exclusive rights to use these patents while Bioheart will receive milestone payments and royalties based on sales of potential products.

    Leading the team at Bioheart is Mike Thomas who serves as the President and CEO of the company. Thomas stated, “Bioheart is currently focused on our core technology of muscle stem cells for congestive heart failure patients and we are excited about the opportunity to work with Airspeed to bring other Bioheart technologies to market.”

    Alan Remen whom serves as the Managing Director of Airspeed Equity added, “Bioheart’s patents fit perfectly within our medical industry strategy. We are pleased Bioheart selected us to commercialize what we believe will be successful products that can improve people’s lives.”

    Commenting on the potential of the patents, Bioheart Co-found and Chief Technology Officer Howard Leonhardt added, “The discovery that low voltage electrical stimulation of the heart can both regenerate damaged heart tissue and replace high voltage implantable defibrillators for arrhythmia fibrillation recovery may change the course of care for the more than 30 million patients suffering of heart failure worldwide.”

    Currently, Bioheart is trading in the $0.147 range. To learn more about this press release or the company as a whole, visit the company website at: bioheartinc.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

     
    Stocks: BHRT
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.